Sha N. Zhao

State Key Laboratory Of Bioreactor Engineering
Shanghai, 200237, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Characteristics of non-small cell lung carcinoma with trophoblastic differentiation in males: a clinicopathological analysis of 16 cases

Characteristics of non-small cell lung carcinoma with trophoblastic differentiation in males: a clinicopathological analysis of 16 cases

Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology

Published: April 30, 2025

Effects of sampling methods on evaluating post-treatment pathological response in resected non-small cell lung cancer specimens with diameter greater than 3 cm

Effects of sampling methods on evaluating post-treatment pathological response in resected non-small cell lung cancer specimens with diameter greater than 3 cm

Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology

Published: April 30, 2025

Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1/L1 therapy (BOOSTER): a randomized phase 2 trial.

Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1/L1 therapy (BOOSTER): a randomized phase 2 trial.

Journal: Signal transduction and targeted therapy

Published: April 03, 2025

Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.

Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.

Journal: BMC medicine

Published: September 20, 2024

Evaluating efficacy and safety of a novel registration-free CT-guided needle biopsy navigation system (RC 120): A multicenter, prospective clinical trial.

Evaluating efficacy and safety of a novel registration-free CT-guided needle biopsy navigation system (RC 120): A multicenter, prospective clinical trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 25, 2024

Camrelizumab, an Anti-PD-1 Monoclonal Antibody, Plus Carboplatin and Nab-Paclitaxel as First-Line Setting for Extensive-Stage Small-Cell Lung Cancer: A Phase 2 Trial and Biomarker Analysis.

Camrelizumab, an Anti-PD-1 Monoclonal Antibody, Plus Carboplatin and Nab-Paclitaxel as First-Line Setting for Extensive-Stage Small-Cell Lung Cancer: A Phase 2 Trial and Biomarker Analysis.

Journal: MedComm

Published: July 03, 2024

Advances in pathological study of micropapillary lung adenocarcinoma

Advances in pathological study of micropapillary lung adenocarcinoma

Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology

Published: October 29, 2023

Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.

Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.

Journal: BMC medicine

Published: July 08, 2023

Dynamics of base pairs with low stability in RNA by solid-state nuclear magnetic resonance exchange spectroscopy.

Dynamics of base pairs with low stability in RNA by solid-state nuclear magnetic resonance exchange spectroscopy.

Journal: iScience

Published: June 09, 2022

Analysis of prognostic and therapeutic values of drug resistance-related genes in the lung cancer microenvironment.

Analysis of prognostic and therapeutic values of drug resistance-related genes in the lung cancer microenvironment.

Journal: Translational cancer research

Published: September 05, 2021

Percutaneous Microwave Coagulation Therapy: A Promising Therapeutic Method for Breaking the Barrier of the Intertumor Heterogeneity.

Percutaneous Microwave Coagulation Therapy: A Promising Therapeutic Method for Breaking the Barrier of the Intertumor Heterogeneity.

Journal: Journal of healthcare engineering

Published: July 26, 2021

Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer.

Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer.

Journal: Journal for immunotherapy of cancer

Published: June 17, 2021

Showing 1-12 of 61

Last Updated: 09/26/2026